This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rad, A. N. Articles by Katz, D. R. Search for Related Content PubMed PubMed Citation Articles by Rad, A. N. Articles by Katz, D. R.

The Differential Influence of Allogeneic Tumor Cell Death via DNA Damage on Dendritic Cell Maturation and Antigen Presentation

Department of Immunology, Windeyer Institute of Medical Sciences, University College London, London W1T 4JF, United Kingdom

Dendritic cells (DCs) respond to danger signals from tissue injury by amplifying their immune-inducing capacity. In the cancer context, this may lead to in vivo antitumor synergism between DCs and DNA-damaging chemotherapeutic agents. Neither the interaction between DCs and dying tumor cells nor whether different ways of inducing cell injury can deliver danger signals of different strength to DCs nor the potential role of damaged DNA as a danger signal has been studied rigorously. Here we report that coculture of immature DCs with tumor cells treated with the alkylating agents melphalan and chlorambucil leads to enhanced autologous and allogeneic T-cell activation, up-regulation of surface expression of MHC and costimulatory molecules, and increased interleukin (IL)-12 secretion. Exposure of the same DCs to tumor cells killed by cytarabine or by freeze-thaw (primary necrosis) resulted in significantly less T-cell proliferation and IL-12 production, indicating that DCs are able to sense and respond differentially to the mode of cell death. Exposure of DCs to DNA purified from tumor cells treated with alkylating agents also increased their T-cell-stimulating capacity, expression of CD86, and IL-12 secretion, supporting the hypothesis that the activating effects of tumor cells are linked to the nature of the DNA damage. This is the first study that shows that DCs respond differentially to killed tumor cells, depending upon the mechanism of DNA damage and consequent cell death.

This article has been cited by other articles:

				C. L-L. Chiang, J. A. Ledermann, E. Aitkens, E. Benjamin, D. R. Katz, and B. M. Chain Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor Clin. Cancer Res., August 1, 2008; 14(15): 4898 - 4907. [Abstract] [Full Text] [PDF]

				U. Johansson, L. Walther-Jallow, A. Smed-Sorensen, and A.-L. Spetz Triggering of Dendritic Cell Responses after Exposure to Activated, but Not Resting, Apoptotic PBMCs J. Immunol., August 1, 2007; 179(3): 1711 - 1720. [Abstract] [Full Text] [PDF]

				A. J. Muller and G. C. Prendergast Marrying Immunotherapy with Chemotherapy: Why Say IDO? Cancer Res., September 15, 2005; 65(18): 8065 - 8068. [Abstract] [Full Text] [PDF]

				S. Baumann, A. Dostert, N. Novac, A. Bauer, W. Schmid, S. C. Fas, A. Krueger, T. Heinzel, S. Kirchhoff, G. Schutz, et al. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer Blood, July 15, 2005; 106(2): 617 - 625. [Abstract] [Full Text] [PDF]